跳至主要内容
临床试验/JPRN-UMIN000035079
JPRN-UMIN000035079已完成未知

A Single Arm Trial of Continuous 24-week-intervention with Designated Treatment Application for Essential Hypertension in addition to hypertension treatment in accordance with guideline - A Single Arm Trial of Continuous 24-week-intervention with Designated Treatment Application for Essential Hypertension in addition to hypertension treatment in accordance with guideline

CureApp, Inc.0 个研究点目标入组 14 人开始时间: 2018年11月30日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
CureApp, Inc.
入组人数
14

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients with severe hypertension, a history of secondary hypertension, cardiovascular / cerebrovascular events, etc

研究者

发起方
CureApp, Inc.

相似试验

进行中(未招募)
1 期
A 24 week, open label single arm study to evaluate the safety and efficacy of switching a toxicity causing antiretroviral (ARV) to enfuvirtide (ENF) and to assess resolution or improvement of ARV toxicities in patients with current, historical treatment-limiting toxicities - SWITCH TOX studyHIV infectionClassification code 10020161
EUCTR2004-001224-21-ESF. Hoffmann-La Roche Ltd300
进行中(未招募)
不适用
A 24 week, open label single arm study to evaluate the safety and efficacy of switching a toxicity causing antiretroviral (ARV) to enfuvirtide (ENF) and to assess resolution or improvement of ARV toxicities in patients with current, historical treatment-limiting toxicities - SWITCH TOX studyHIV infectionClassification code 10020161
EUCTR2004-001224-21-DEF. Hoffmann-La Roche Ltd300
进行中(未招募)
不适用
A 24 week, open label single arm study to evaluate the safety and efficacy of switching a toxicity causing antiretroviral ARV to enfuvirtide ENF and to assess resolution or improvement of ARV toxicities in patients with current, historical treatment-limiting toxicity.treatment of HIV-1 infected patientsMedDRA version: 9.1Level: LLTClassification code 10000807Term: Acute HIV infection
EUCTR2004-001224-21-ITROCHE300
招募中
不适用
A Clinical Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical MonoPointTM Reperfusion SystemTM for Aspiration Embolectomy in Acute Ischemic Stroke PatientsAcute Ischemic StrokeStroke - IschaemicNeurological - Other neurological disorders
ACTRN12619000890134Route 92 Medical, Inc.15
已完成
不适用
carnitine supplementation for Neurofibromatosis type 1 muscle weakness and fatigue.Neurofibromatosis type 1eurofibromatosis type 1Musculoskeletal - Other muscular and skeletal disordersMetabolic and Endocrine - Other metabolic disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disorders
ACTRN12618002021257The Children's Hospital at Westmead6